Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update
13. November 2024 06:30 ET
|
Liquidia Corporation
Liquidia Corporation (LQDA) today reported financial results for the third quarter ended September 30, 2024.
Liquidia to Present at the Stifel 2024 Healthcare Conference
12. November 2024 08:00 ET
|
Liquidia Corporation
Liquidia Corporation (LQDA) to present at the Stifel 2024 Healthcare Conference in New York City on Tuesday, November 19, 2024, from 3:00 – 3:30 p.m. ET.
Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 13, 2024
06. November 2024 08:00 ET
|
Liquidia Corporation
Liquidia Corporation (LQDA) to report its third quarter 2024 financial results on November 13, 2024, via webcast at 8:30 a.m. ET
Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 11, 2024
04. November 2024 08:00 ET
|
Liquidia Corporation
Liquidia Corporation (NASDAQ: LQDA), to report its third quarter 2024 financial results via webcast at 8:30 a.m. ET on Friday, November 8, 2024.
Bragar Eagel & Squire, P.C. Is Investigating Liquidia, Napco, and Franklin and Encourages Investors to Contact the Firm
30. September 2024 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Liquidia Corporation...
Liquidia Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting
30. September 2024 08:00 ET
|
Liquidia Corporation
Liquidia will present a poster and host a medical theater at the CHEST 2024 annual meeting hosted by the American College of Chest Physicians this October.
Bragar Eagel & Squire, P.C. Is Investigating Paragon 28, Centuri, Liquidia, and Elastic and Encourages Investors to Contact the Firm
16. September 2024 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Paragon 28, Inc. (NYSE:...
Court Finds United Therapeutics’ Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million
16. September 2024 09:41 ET
|
Liquidia Corporation
MORRISVILLE, N.C., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia), a biopharmaceutical company developing innovative therapies for patients with rare...
LIQUIDIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Liquidia Corporation on Behalf of Liquidia Stockholders and Encourages Investors to Contact the Firm
27. August 2024 22:00 ET
|
Bragar Eagel & Squire
NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Liquidia Corporation...
Liquidia Files Litigation to Challenge Regulatory Exclusivity Blocking Access to YUTREPIA™ (treprostinil) inhalation powder for Patients Suffering with PAH and PH-ILD
22. August 2024 06:00 ET
|
Liquidia Corporation
Liquidia has filed litigation that challenges the recent decision by the FDA to grant 3-year new clinical investigation exclusivity to Tyvaso DPI.